Angiotensin II (ANG II) is a well-established participant in many cardiovascular disorders, but the mechanisms involved are not clear. Vascular cell experiments suggest that ANG II is a potent stimulator of free radicals such as superoxide anion, an agent known to inactivate nitric oxide and promote the formation of peroxynitrite. Here we hypothesized that ANG II reduces the efficacy of NO-mediated vascular relaxation and promotes vascular peroxynitrite formation in vivo. ANG II was infused in rats at sub-pressor doses for 3 days. Systolic blood pressure and heart rate were unchanged on day 3 despite significant reductions in plasma renin activity. 
Angiotensin II (ANG II) is a well-recognized participant in many cardiovascular diseases, and its production or activity are currently important targets in cardiovascular pharmacology and medicine (ACE inhibitors and ANG II receptor antagonists) (1, 2) . Early studies of this hormone demonstrated its potent vasoconstrictive actions, while more recent studies have defined important effects on vascular cell growth, differentiation, and gene expression (3, 4, 5) . Recent studies using isolated vascular cells demonstrate that ANG II promotes the production of oxygen radicals (particularly superoxide anion) (6, 7) , and this may be an important component of ANG II-mediated cardiovascular disease (8, 9) . Although a role for ANG II in cardiovascular disease is well established, the mechanisms by which it participates have not been elucidated. In particular, the early and initiating events during elevated ANG II levels in vivo are not well defined.
In the last decade, recognition of the importance of vascular endothelial cells for maintenance and regulation of vascular health has emerged (10, 11) . Nitric oxide (NO) derived from vascular endothelial cells has been shown to be a critical modulator of local vascular tone and thrombus formation; deficient endothelial NO production has been demonstrated in a wide array of cardiovascular diseases including hypertension, atherosclerosis, unstable angina, and congestive heart failure (10, 11, 12) . The chemistry of NO in biological matrices is very complex, and several biochemical pathways other than NO production can influence NO actions (13, 14) . For example, superoxide anion interacts with NO, reduces its efficacy as a signal transduction agent, and promotes the formation of peroxynitrite, a highly reactive intermediate known to nitrate protein tyrosine residues and cause cellular oxidative damage (15, 16) . The reaction of NO with superoxide anion occurs at a diffusion-limited reaction rate and NO is the only molecule known to compete with superoxide dismutase for its substrate in a biological setting (17, 18, 19) . Thus, excess or uncontrolled superoxide anion formation can shift the actions of available NO from a useful cellular signal to peroxynitrite and redox-related toxic products.
While dysfunction of vascular endothelium and elevated blood concentrations of ANG II are each commonly observed in many forms of cardiovascular disease, few studies have evaluated the relationships between these phenomena. Here we investigated the actions of ANG II in vivo, testing the hypotheses that sub-pressor ANG II causes selective vascular dysfunction and that vascular peroxynitrite formation (and attendant dysregulation of NO control) participates in this phenomenon.
MATERIALS AND METHODS

Animal model and angiotensin administration
Osmotic mini-pumps (Alza Corp., Palo Alto, Calif.) were used to provide continuous ANG II administration for 3 consecutive days in rats (male Sprague Dawley, 325-350 g). Intraperitoneal implantation was conducted during pentobarbital anesthesia using a sterile surgical technique. ANG II (200 ng⅐kg Ϫ1 ⅐min Ϫ1 ) or saline vehicle was administered at a flow rate of 1.0 l/h. The dose used here has been shown by others to be a 'slow-pressor dose' in rats, producing no significant elevation of systemic blood pressure until 7 days of continuous administration (4, 5) . ANG II was kindly supplied by Bachem Biosciences Inc. (King of Prussia, Pa.). Prior to pump implantation (day 0) and on day 3 of infusion, systemic blood pressure and heart rate were evaluated in conscious rats using a tail cuff apparatus (Stoelting Instruments, Wood Dale, Ill.). After pentobarbital overdose (75 mg/kg i.p.), blood was rapidly collected by cardiac puncture and vascular tissues were rapidly isolated.
Plasma renin activity
Blood was collected by cardiac puncture at death and plasma was rapidly collected. Plasma renin activity was measured by a commercially available radioimmunoassay kit adapted for lowvolume samples (Incstar, Stillwater, Minn.). Activity was determined as nanogram of angiotensin I produced per ml/h. Intra-day and inter-day assay variability was less than 10%.
Isolated vascular studies
After animals were killed, the thoracic aorta was rapidly isolated for functional evaluations using methods similar to those previously described (20, 21) . Vascular segments (2-3 mm) were mounted on isometric force transducers (Grass Instruments, Quincy, Mass.) and incubated in 10 ml organ baths containing Krebs' buffer bubbled with 95% O 2 at 37°C. After 90 min equilibration (resting tone 1.0 g), maximal contractile force was determined for each segment using a high potassium concentration (modified Kreb's buffer containing 14.4 mM NaCl and 125 mM KCl). This complete depolarization was used to define maximal contractile response and was considered 100% contraction. Segments were then consecutively washed with Krebs' buffer four times, with two 5 min intervals and two 10 min intervals, and allowed to equilibrate for 30 min. Cumulative responses to cumulative concentrations of phenylephrine were then determined. In parallel studies, in vitro responses to ANG II were evaluated by single exposure of concentrations ranging from 1 nM to 1 M (thus preventing development of tachyphylaxis).
After precontraction with phenylephrine at 80% of maximum, relaxant responses to cumulative acetylcholine were assessed. In preliminary experiments, acetylcholine relaxation was completely blocked by 200 M L-nitroarginine (a nonspecific NOS inhibitor); thus, the vasodilatory response is apparently endothelium dependent and NO mediated in this vascular tissue. Relaxant responses to cumulative sodium nitroprusside were also determined (an endothelium independent but NO-mediated response) (22) . Contractile and relaxant response data were fit to the 4-parameter logistic equation using GraphPad Prism Software (GraphPad Software, Inc., San Diego, Calif.) (20, 21) .
Immunohistochemistry
Immunohistochemistry was performed to determine the relative extent of protein nitration (a stable biomarker of endogenous peroxynitrite formation), using an antibody raised against 3-nitrotyrosine (3-NT). A section of aorta from each rat, separated from the isolated vascular tissue studies, was fixed in formalin and embedded in paraffin. Aorta cross sections were cut into 5 m sections, deparaffinized, and rehydrated. Tissues were then exposed to a 3% hydrogen peroxide/methanol solution for 10 min to block endogenous peroxidase activity. To restore antigenicity, slides were immersed for 15 min in a 10 mM citrate buffer (pH 6) preheated to boiling. Sections were incubated for 30 min in a 10% normal goat serum/phosphate-buffered saline solution to block nonspecific antibody binding. Tissue sections were incubated with rabbit anti-mouse polyclonal antibody raised against 3-NT (1:200 dilution, Upstate Biotechnology, Lake Placid, N.Y.) for 1 h. Biotinylated secondary anti-rabbit serum was then applied (1:200), followed by horseradish peroxidase complex reagent (ABC Elite, Vector Laboratories, Burlingame, Calif.). Positive immunoreactivity was visualized through the development of diaminobenzidine (DAB) chromogen. Harris' modified hematoxylin was used for nuclear counterstaining. Preliminary experiments were conducted to verify the specificity of immunostaining in our laboratory. Preincubation of primary antibody with free 3-NT (1 mM) completely quenched positive tissue staining, whereas tyrosine (1 mM) had no effect. Nonimmune serum (isotypic) controls also showed no detectable immunoreactivity in any treatment group.
Digital image analysis
Images of immunostained tissue were captured using an Olympus microscope (BX-40) and a high-resolution digital camera (Pixera, Inc., 1260ϫ960 pixel resolution). Unmodified images were analyzed using research-based image analysis software (ImagePro Plus, Media Cybernetics, Md.). Six endothelial regions of each aortic ring were systematically captured at 200ϫ, representing ϳ45% of the total vascular endothelium circumference. Relative extent of 3-NT immunoreactivity was assessed using digital color image analysis. Similar to other reports (23), we observed the most striking difference in 'positive' vs. background staining regions in the blue channel of RGB color profile (i.e., red, green, blue). There was a well-defined segmentation of the intensity profile such that brown DAB staining registers between 0 and 100 intensity units, whereas shades of blue or white background were consistently greater than 100 intensity units, as shown in Fig. 4 . For each vascular image, the percentage of positive pixels in the captured images was used as an objective and semi-quantitative measure of immunoreactivity (24), allowing statistical comparisons among groups (25) . Intra-observer variability was consistently less than 12% (coefficients of variation from 3 daily measurements), whereas inter-observer variability was less than 10% (coefficients of variation of average measurements between three observers collecting six images on three different days).
Statistical analyses
All data are presented as mean Ϯ se. Statistical evaluations were performed using Sigmastat software ( Jandel Scientific Inc., San Rafael, Calif.). Comparisons among treatment groups were performed using Student's t tests or analysis of variance where appropriate (26) . Spearman nonparametric correlation analysis was used to test for significant association of functional and immunohistochemical data (26) . In all cases, P Ͻ 0.05 was deemed statistically significant.
RESULTS
Figure 1
shows changes in plasma renin activity, hemodynamics, and cardiac mass after ANG II or vehicle infusion for 3 days. Statistically significant reductions in plasma renin activity were observed by day 3 after ANG II administration relative to vehicle infusion, illustrating hormonal feedback of the renin-angiotensin axis and demonstrating successful infusion of low-dose ANG II. There was no significant change in plasma aldosterone concentrations (data not shown). In contrast, ANG II did not cause significant changes in systolic blood pressure or heart rate by day 3 (Fig. 1) . Similarly, no significant change in body weight, total heart weight, or left ventricular weight (all parameters known to be affected at higher ANG II exposures) was observed by day 3. Aortic cross sectional areas were also unaffected by ANG II infusion (data not shown).
Isolated vascular contractile responses are shown in Fig. 2 . Maximal vascular contractile response to total depolarization (125 mM KCl) was not different between ANG II and vehicle-infused groups. Contractile responses to the ␣-receptor agonist phenylephrine were also unaltered (EC 50 49Ϯ12 vs. 73Ϯ14 nM; Emax 1.09Ϯ0.06 vs. 0.99Ϯ0.06 g; ANG II vs. control, respectively). Contractile response to ANG II in vitro was not statistically affected by 3 day infusion (EC 50 280Ϯ110 vs. 183Ϯ41 nM; Emax 0.41Ϯ0.12 vs. 0.34Ϯ0.8 g; ANG II infused vs. control, respectively).
Despite unaltered vascular contractile properties, significant alteration in acetylcholine-induced relaxation was observed (Fig. 3) . A statistically significant sixfold reduction in EC 50 (390Ϯ12 vs. 64Ϯ13 nM, ANG II infused vs. vehicle infused) was observed, with no change in maximal relaxant response (Emax 93Ϯ4 vs. 109Ϯ4). No significant differences in extent of phenylephrine-induced precontraction were observed among treatment groups.
In contrast to diminished acetylcholine responses, no significant change in vasorelaxant response to the endothelium independent and 'spontaneous' NO donor sodium nitroprusside was observed between treatments (Fig. 3, EC Representative photomicrographs of vascular immunostaining for 3-NT are shown in Fig. 4 . Extensive protein nitration was observed in the vasculature from ANG II-treated animals and was found nearly Figure 4 also shows the distinct color distribution patterns for diaminobenzidine (positive signal for 3-NT immunohistochemistry) and hematoxylin counterstain. This distinction was used to determine the percentage of the cross sectional area considered a positive signal using digital image analysis (see Materials and Methods).
Digital image analysis demonstrated statistically significant increases in vascular 3-NT immunoprevalence from ANG II-treated animals relative to vehicle infusion controls (Fig. 4) . This difference was confined to the endothelial layer (no significant differences were observed when regions of exclusively vascular smooth muscle were compared; see Fig. 5 ). In addition to comparing the two treatment groups, controls were used to evaluate sensitivity and selectivity of the primary 3-NT antibody. The positive immunostaining signal could be completely abolished by preincubation of primary antibody with free nitrotyrosine in solution (1 mM) or by replacing it with preimmune serum. Significant 3-NT immunoprevalence was observed in the vehicle treatment group when compared to these staining controls, demonstrating a slight but detectable protein nitration (and corresponding peroxynitrite production) under control conditions (Fig. 5, top panel) .
The relationship between the prevalence of endothelial protein nitration and endothelium-dependent functional response to acetylcholine is shown in Fig. 5 (bottom panel) . Measurements of 3-NT immunoprevalence (using image analysis) and acetylcho- line EC 50 were related for each animal in the study. A highly statistically significant inverse correlation was observed between the extent of intimal protein nitration and endothelium-dependent acetylcholine functional response (PϽ0.02, Spearman nonparametric correlation analysis).
DISCUSSION
First identified as a potent vasoconstrictor in the 1950s, angiotensin II now represents a pivotal therapeutic target for the management of many forms of cardiovascular disease. For example, inhibition of ANG II formation (through the use of angiotensin converting enzyme inhibitors) or selective blockade of ANG II receptors have been shown to be valuable for the treatment of essential hypertension, congestive heart failure, and coronary artery disease (1, 2) . Even though ANG II was first recognized as a vasoconstrictor, its roles are now known to be diverse, including stimulation of cardiac and vascular cell growth and division, and activation of vascular NADH/NADPH oxidase activity (1) (2) (3) (4) (5) (6) . Given these diverse hormonal influences, the long-term value of ANG II inhibition for cardiovascular disease may be mediated by nonhemodynamic actions rather than acute vasorelaxant effects per se (2) .
The vascular endothelium plays a key role in the local regulation of vasomotor tone and prevention of thrombus formation. Using agents like acetylcholine or changes in flow to stimulate the release of NO (e.g., endothelium-derived relaxing factor, EDRF), clinical studies have demonstrated the importance of EDRF/NO in both basal and stimulated control of vascular tone (10 -12) . Dysfunction of vascular endothelium (particularly decreased activity of NO-dependent pathways) has been associated with a wide array of cardiovascular risk factors including chronic smoking, hypercholesterolemia, hypertension, and chronic heart failure (10 -12, 27) . Loss of endothelial integrity is known to promote vascular remodeling and thrombus formation, to impair tissue perfusion (particularly during stress), and to result in vasoconstriction (11) . Thus, endothelial dysfunction is associated with a diverse array of cardiovascular disease states and may be an important initiator of these progressive conditions. Inhibition of angiotensin-converting enzyme (ACE) has recently been shown improve endothelial function in patients with coronary artery disease or its risk factors (TREND; Trial on Reversing Endothelial Dysfunction). In this large-scale clinical trial, treatment with quinapril (an ACE inhibitor with affinity for vascular tissue) for 6 months was associated with a significantly improved vasodilator response to acetylcholine in coronary artery segments (28) . Similar improvements were also observed in microvasculature (29) . These clinical findings suggest that angiotensin has important influence on endothelium in vivo and that some benefit of ACE inhibitor therapy is mediated by improving endothelial function in vivo, but the mechanisms involved have not been established.
Recent studies have demonstrated that ANG II is an activator of superoxide production in several cell types, including fibroblasts (30), mesangial cells (31), and endothelial cells (32) . This stimulation is apparently mediated by the AT 1 receptor subtype activation, leading to increased gene expression of NADH/NADPH oxidase subunits p67phox (33), p22phox (34) , and perhaps others. The role of this enhanced oxidase expression in ANG II-mediated actions is not clear but it may contribute to the other known cellular responses (e.g., proliferation, hypertrophy, etc.). Whereas isolated endothelial cell studies have demonstrated the selective presence of AT1 receptors (and an apparent absence of the AT 2 subtype) (32) , whether the endothelium plays a direct role in ANG II-related cardiovascular disease in vivo has not been established. Given previous reports of ANG II promotion of vascular superoxide formation and the newly recognized importance of endothelial NO for vascular health, we hypothesized here that ANG II in vivo would selectively modify endothelium-dependent function. Recent investigations have demonstrated that the biological activities of NO are highly dependent on both productionand destruction-related pathways (13) . A chemical pathway of biological importance appears to be the formation of peroxynitrite through the interaction of NO with superoxide anion. This reaction is exceedingly rapid and efficient (1.9ϫ10 10 M Ϫ1 s Ϫ1 ; see ref 19) , leading to reduced levels of available NO and formation of a highly reactive oxidant in vivo (17) (18) (19) . Peroxynitrite and related species aggressively nitrate protein tyrosine residues, leading to the chemically stable biomarker 3-NT (16) . We and others have demonstrated the value of this marker as evidence of NO dysregulation in disease, including advanced atherosclerotic lesions (35) , sepsis-related organ failure (36) , renal transplant rejection (37) , and others.
The ANG II infusion used in our studies (200 ng⅐kg Ϫ1 ⅐min Ϫ1 ) caused significant inhibition of plasma renin activity but no change in systemic blood pressure or cardiac mass on day 3. This dosing strategy appears to be physiologically relevant since it has been shown to produce steady-state ANG II blood levels similar to those observed in hypertensive animals and humans (ϳ100 pg/ml) (38) . This strategy of a short-term, 'slow pressor dose' administration allowed us to evaluate early vascular changes during ANG II elevations in the absence of detectable cell growth or hemodynamic influences. No significant change in vascular response was observed for total depolarized contraction, ␣-adrenergic stimulation, or ANG II contractions. Using an identical animal model but more prolonged ANG II dosing [120 ng/(min⅐kg of 21 days)], Dowell et al. (39) observed significant potentiation of adrenergic contractile activities, likely due to increased vascular smooth muscle cell growth over 3 wk. In contrast, we observed significant reduction in acetylcholine-induced vasorelaxation prior to any changes in contractile responses and after only 3 days of elevated blood ANG II. This endothelium-dependent relaxant response is mediated by NO formation from the constitutively expressed nitric oxide synthase within endothelial cells (NOS III) (10) . Once formed, endothelium-derived NO apparently diffuses to vascular smooth muscle cells and elicits relaxation via cyclic GMP-dependent pathways (22) . In contrast to diminished acetylcholine response, no change in nitroprusside action was found. Nitroprusside is an exogenous agent that generates NO through nonenzymatic and enzymatic pathways in smooth muscle cells and does not require functional endothelium or NOS enzymes for activity. Since vascular smooth muscle response to an exogenous NO source (nitroprusside) was not altered, the diminished response to acetylcholine was apparently related to either decreased endothelial production of NO or reduced bioavailability to effector smooth muscle cells.
Consistent with selective endothelium dysfunction, we also observed intima-specific staining for protein 3-NT residues. Given the extremely rapid reaction rates for peroxynitrite formation from NO and superoxide (known to be diffusion rate limited) and from protein nitration, the staining pattern observed suggests that peroxynitrite was concentrated in or near the endothelial layer. In addition to serving as a biomarker of peroxynitrite, nitration of protein tyrosine residues is known to be an inhibitor of several biochemical pathways including mitochondrial respiration (40) , high-energy phosphate utilization (41), prostaglandin synthesis (42) , and superoxide dismutase activity (43) . Peroxynitrite can also induce DNA strand breakage in human umbilical vein endothelial cells (44) . Thus, endothelial formation of peroxynitrite (through interaction of NO with superoxide) is likely to reduce availability of NO to vascular smooth muscle as well as have functional consequences to endothelial cell biochemistry. We recently reported a distinctly different vascular 3-NT staining pattern during development of organic nitrate pharmacodynamic tolerance (widespread distribution throughout smooth muscle) (45) . Thus, peroxynitrite formation and protein nitration may exist in a variety of vascular disorders, but the mechanisms involved and cellular distributions may be distinct and depend on the stimuli involved. While recent studies have suggested the existence of other potential biological pathways of tyrosine nitration, these studies have demonstrated that the chemistries responsible are dependent on neutrophil infiltration and activation (46, 47) . Since we did not observe immune cell involvement in our vascular studies, the protein nitration observed here is most likely derived from ONOO Ϫ formation. In addition, previous studies demonstrate that cardiovascular tis-sue homogenates require exogenous addition of neutrophil myeloperoxidase (5 M), 1 mM concentrations of nitrite and hydrogen peroxide, and long incubation times (Ͼ1 h) to produce detectable protein nitration (46) . In contrast, NO and superoxide anion are known to form OONO Ϫ at a diffusionlimited rate, even at very low concentrations. Under our experimental conditions, therefore, the observed protein nitration may be explained most simply by increased peroxynitrite formation rather than more complicated or less efficient chemical processes.
In summary, we found that low-dose and shortterm administration of ANG II caused a selective reduction in endothelium-dependent (nitric oxidemediated) relaxant effects. These changes occurred prior to any other established consequences of elevated ANG II in vivo, including enhanced vascular contractile responses, development hypertension, or increase in cardiac or vascular mass. Further evaluations revealed that this endothelial dysfunction was associated with increased production of peroxynitrite in vivo. Protein nitration in the endothelial layer correlated with the extent of functional impairment observed. Thus, selective perturbation of normal endothelial function is an apparent early or initiating event during ANG II exposure in vivo. Furthermore, vascular peroxynitrite formation (and attendant NO dysregulation) may mediate these early events during ANG II-induced vascular dysfunction in vivo. Our findings may help to explain the results of the recently published TREND trial (see above), and suggest that evaluation of selective endothelial therapies for the prevention of disease appears warranted.
